VERVE-102 just published Phase 1b data in NEJM. Single IV infusion. 88% PCSK9 reduction. 62% LDL-C reduction. 18-month durability. No serious adverse events in 35 patients.
But the core problem being solved is not efficacy. Statins work. PCSK9 inhibitors work. The problem: roughly half of patients prescribed lipid-lowering therapy stop taking it within a year. Every year. Consistently.
Adenine base editing does not cut DNA. It converts a single nucleotide letter in the PCSK9 gene in liver cells. No double-strand break. The target mimics a natural human variant already field-tested by evolution.
The 18-month durability signal is the most important data point in the whole dataset - not the peak LDL reduction. For a one-time treatment, everything hinges on whether the effect persists.
Subscribe to www.onhealthcare.tech for free and paid articles, podcasts, and more.
